Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose ...
NEW YORK CITY, NY, UNITED STATES, March 3, 2025 /EINPresswire.com/ -- Creative Bioarray, a premier provider of innovative life science solutions, is proud to announce ...
ZURICH, SWITZERLAND / ACCESSWIRE / June 14, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and ...
Recent evidence highlights the complex interplay between the central nervous system and hepatic drug-metabolising enzymes. In particular, the regulation of liver cytochrome P450 (CYP) enzymes by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback